Sangamo Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SGMO research report →
Companywww.sangamo.com
Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression.
- CEO
- Alexander D. Macrae Ch.B
- IPO
- 2000
- Employees
- 183
- HQ
- Richmond, CA, US
Price Chart
Valuation
- Market Cap
- $66.29M
- P/E
- -0.51
- P/S
- 1.92
- P/B
- -3.29
- EV/EBITDA
- -0.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 95.83%
- Op Margin
- -319.25%
- Net Margin
- -356.89%
- ROE
- 6686.36%
- ROIC
- -1606.07%
Growth & Income
- Revenue
- $39.55M · -31.57%
- Net Income
- $-122,932,000 · -25.52%
- EPS
- $-0.44 · 10.20%
- Op Income
- $-108,004,000
- FCF YoY
- -44.36%
Performance & Tape
- 52W High
- $0.77
- 52W Low
- $0.10
- 50D MA
- $0.25
- 200D MA
- $0.44
- Beta
- 1.04
- Avg Volume
- 10.33M
Get TickerSpark's AI analysis on SGMO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | Davis Gregory D | sell | 69,827 |
| Apr 21, 26 | Dubois-Stringfellow Nathalie | sell | 345,942 |
| Apr 1, 26 | Dubois-Stringfellow Nathalie | other | 800,000 |
| Apr 1, 26 | Jain Nikunj | other | 225,000 |
| Apr 1, 26 | Davis Gregory D | other | 225,000 |
| Apr 1, 26 | Macrae Sandy | other | 2,500,000 |
| Apr 1, 26 | Willoughby Scott B. | other | 800,000 |
| Feb 24, 26 | Dubois-Stringfellow Nathalie | other | 2,063 |
| Feb 25, 26 | Dubois-Stringfellow Nathalie | other | 12,354 |
| Feb 24, 26 | Macrae Sandy | other | 5,291 |
Our SGMO Coverage
We haven't published any research on SGMO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SGMO Report →